Time response of cytochrome P450 1A2 activity on cessation of heavy smoking
- PMID: 15289794
- DOI: 10.1016/j.clpt.2004.04.003
Time response of cytochrome P450 1A2 activity on cessation of heavy smoking
Abstract
Background and objective: Cytochrome P450 (CYP) 1A2 activity is induced by cigarette smoking. Thus smoking cessation in patients while they are undergoing therapy with a CYP1A2 substrate such as theophylline or clozapine increases its concentrations and may cause adverse effects. Our objective was to determine the time course of CYP1A2 activity changes after smoking cessation in heavy smokers as the basis for dosing adaptation schemes.
Methods: The study was conducted in 8 men and 4 women (all white) who smoked 20 cigarettes or more per day. Sudden smoking cessation was carried out after a 14-day run-in period. Subjects were phenotyped for CYP1A2 activity at 6, 4, and 1 day before smoking cessation and at 0, 1, 2, 3, 6, 8, 10, and 13 days thereafter by use of the paraxanthine-to-caffeine ratio in plasma 6 hours after a 148-mg caffeine test dose. A monoexponential decay of CYP1A2 activity to a residual value was fitted to the data by nonlinear regression analysis.
Results: On cessation of smoking, initial caffeine clearance (estimated geometric means and 95% confidence intervals) decreased significantly (P <.01), by 36.1% (30.9%-42.2%), from 2.47 mL. min(-1). kg(-1) body weight (2.03-3.00 mL. min(-1). kg(-1) body weight) to a new steady state of 1.53 mL. min(-1). kg(-1) body weight (1.24-1.89 mL. min(-1). kg(-1) body weight). The apparent half-life of CYP1A2 activity decrease was 38.6 hours (27.4-54.4 hours).
Conclusion: Doses of CYP1A2 substrates with a narrow therapeutic range should be decreased immediately on cessation of heavy smoking. As a rule of thumb, a stepwise daily dose reduction of approximately 10% until the fourth day after smoking cessation is proposed, which should be accompanied by therapeutic drug monitoring.
Similar articles
-
Effects of cigarette smoking and carbon monoxide on chlorzoxazone and caffeine metabolism.Clin Pharmacol Ther. 2003 Nov;74(5):468-74. doi: 10.1016/j.clpt.2003.07.001. Clin Pharmacol Ther. 2003. PMID: 14586387 Clinical Trial.
-
Interaction of pefloxacin and enoxacin with the human cytochrome P450 enzyme CYP1A2.Clin Pharmacol Ther. 1999 Mar;65(3):262-74. doi: 10.1016/S0009-9236(99)70105-0. Clin Pharmacol Ther. 1999. PMID: 10096258 Clinical Trial.
-
Effects of major tanshinones isolated from Danshen (Salvia miltiorrhiza) on rat CYP1A2 expression and metabolism of model CYP1A2 probe substrates.Phytomedicine. 2009 Aug;16(8):712-25. doi: 10.1016/j.phymed.2009.03.004. Epub 2009 Apr 28. Phytomedicine. 2009. PMID: 19403289
-
[On the possibility of patient phenotyping on the basis of cytochrome p-450 1A2 isoenzyme activity using caffeine as the test substrate].Eksp Klin Farmakol. 2009 Sep-Oct;72(5):61-5. Eksp Klin Farmakol. 2009. PMID: 19928580 Review. Russian.
-
Assessment of CYP1A2 activity in clinical practice: why, how, and when?Basic Clin Pharmacol Toxicol. 2005 Sep;97(3):125-34. doi: 10.1111/j.1742-7843.2005.pto_973160.x. Basic Clin Pharmacol Toxicol. 2005. PMID: 16128905 Review.
Cited by
-
Effects of smoking cessation on plasma clozapine concentrations in male patients with schizophrenia during the COVID-19 pandemic.Front Psychiatry. 2023 Sep 15;14:1256264. doi: 10.3389/fpsyt.2023.1256264. eCollection 2023. Front Psychiatry. 2023. PMID: 37779619 Free PMC article.
-
Effects of CYP2D6 and CYP2C19 genetic polymorphisms and cigarette smoking on the pharmacokinetics of tolperisone.Arch Pharm Res. 2023 Aug;46(8):713-721. doi: 10.1007/s12272-023-01462-1. Epub 2023 Sep 20. Arch Pharm Res. 2023. PMID: 37728834
-
Study on the daily dose and serum concentration of clozapine in psychiatric patients and possible influencing factors of serum concentration.BMC Psychiatry. 2023 Aug 15;23(1):596. doi: 10.1186/s12888-023-05078-z. BMC Psychiatry. 2023. PMID: 37582705 Free PMC article.
-
Prediction of herb-drug interactions involving consumption of furanocoumarin-mixtures and cytochrome P450 1A2-mediated caffeine metabolism inhibition in humans.Saudi Pharm J. 2023 Mar;31(3):444-452. doi: 10.1016/j.jsps.2023.01.011. Epub 2023 Feb 1. Saudi Pharm J. 2023. PMID: 37026048 Free PMC article.
-
Subsequent ischemic stroke and tobacco smoking: A secondary analysis of the POINT trial.Eur Stroke J. 2023 Mar;8(1):328-333. doi: 10.1177/23969873221148224. Epub 2022 Dec 28. Eur Stroke J. 2023. PMID: 37021190 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous
